Skip to content
PeptideAI
Approved drughormone supportmuscle growthrecovery

Somatrogon

A once-weekly growth hormone fusion protein carrying three copies of the hCG C-terminal peptide, which extend its half-life enough to replace daily injections in children with GH deficiency.

Also known as Somatrogon-ghla, CTP-modified growth hormone, hGH-CTP, Ngenla, MOD-4023, OPKO-GH

Approved drug — Licensed by a major regulator for human use, with phase-3 trial data behind it.

Approved in the EU, Japan, Canada and the US for paediatric GH deficiency on the basis of a phase 3 trial demonstrating non-inferior annual height velocity versus daily somatropin. Injection-site reactions were more common than with daily GH, which is the main practical difference. It has no adult indication in most jurisdictions.

How it works

Somatrogon is human GH genetically fused to one copy of the carboxy-terminal peptide of the hCG beta subunit at the N-terminus and two copies at the C-terminus. These heavily O-glycosylated CTP domains are the same natural half-life-extension mechanism that makes hCG persist far longer than LH, and they increase hydrodynamic radius and negative charge enough to slow renal filtration substantially. Receptor activation is conventional GH receptor dimerisation and JAK2/STAT5 signalling, though intrinsic receptor potency per molecule is reduced by the bulky CTP additions, which is why the weekly milligram dose is much higher than the equivalent weekly somatropin total.

Targets: Growth hormone receptor (GHR), JAK2/STAT5 pathway, Hepatic IGF-1 production

Dosing

ProtocolDoseFrequencyRoute
Paediatric GH deficiency (label)Same day each week, at any time of day, rotating sites.—once weeklysubcutaneous
  • · 0.66 mg per kg body weight once weekly. For a 25 kg child that is 16.5 mg weekly - much larger milligram numbers than somatropin, because CTP adds mass without adding potency.

Titration

Dose is weight-based and recalculated as the child grows; IGF-1 SDS is used to check for over- or under-replacement rather than as the primary titration target.

Cycling

Chronic paediatric replacement therapy continued until epiphyseal closure or growth targets are reached. Not a cycled compound.

Work out your exact syringe units →

Pharmacology

Half-life
Long enough to support once-weekly dosing; roughly on the order of a day and a half, which combined with reduced clearance sustains the weekly interval.
Onset
IGF-1 rises within the first week; growth velocity is assessed at 12 months in children.
Routes
subcutaneous
Molecule
Recombinant hGH fusion protein with C-terminal peptide (CTP) extensions

Handling

Diluent
Not applicable - supplied as a ready-to-use prefilled pen
Vial sizes
24, 60 mg
Lyophilised
Not applicable; store unused pens refrigerated at 2 to 8 degrees C.
Reconstituted
An in-use pen is kept refrigerated and discarded after the labelled in-use period (28 days).
Light sensitive
Yes — keep it out of the light

Mixing

Ngenla comes as a prefilled multi-dose pen in 24 mg/1.2 mL and 60 mg/1.2 mL strengths.

Side effects

  • very commonInjection-site pain, erythema and pruritus— More frequent than with daily somatropin - a recognised trade-off of the larger weekly injection volume.
  • commonHeadache
  • commonPyrexia
  • commonAnti-drug antibody development— Common in trials without demonstrable loss of efficacy or safety impact.
  • uncommonArthralgia
  • uncommonAdrenal insufficiency unmasked— GH class warning.
  • rareIntracranial hypertension
  • rareSlipped capital femoral epiphysis

Do not use if

  • Acute critical illness after open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure.
  • Closed epiphyses when used for growth promotion.
  • Active malignancy.
  • Active proliferative or severe non-proliferative diabetic retinopathy.
  • Prader-Willi syndrome with severe obesity or severe respiratory impairment.
  • Known hypersensitivity to somatrogon or excipients.

Combining it

  • conflictGlucocorticoids — Steroid dose adjustment may be needed; high-dose steroids blunt growth response.
  • conflictOral oestrogen — Blunts the IGF-1 response to GH.
  • cautioninsulin — Insulin requirements may increase.
  • redundantsomatropin — A weekly replacement for daily GH rather than an addition to it.

What to monitor

  • · Growth velocity and height SDS in children.
  • · IGF-1 SDS at a consistent point in the weekly cycle.
  • · Fasting glucose and HbA1c.
  • · Thyroid function and adrenal status.
  • · Fundoscopy for intracranial hypertension symptoms.

Legal status

Approved by the EMA and FDA for paediatric growth hormone deficiency, prescription-only. Prohibited in sport under WADA S2.

References

  • Deal et al. 2022 JCEM, phase 3 trial of once-weekly somatrogon versus daily somatropin in paediatric GH deficiency (trial)
  • Ngenla (somatrogon-ghla) prescribing information (label)

Mechanism in depth

Somatrogon borrows a half-life extension mechanism that evolution already worked out. Human chorionic gonadotropin and luteinising hormone share an identical alpha subunit and closely related beta subunits, yet hCG persists in circulation dramatically longer - and the difference is a 28-residue O-glycosylated extension on the hCG beta subunit's C-terminus. Attaching copies of that peptide to another protein transfers the property. Three copies on GH - one at the N-terminus, two at the C-terminus - increase hydrodynamic radius and negative charge enough that glomerular filtration slows substantially, extending the dosing interval to a week. The cost is potency per molecule. The bulky CTP domains sit near the receptor-binding surfaces and reduce intrinsic receptor activation, which is exactly why the weekly milligram dose is so much larger than the equivalent weekly total of daily somatropin: 0.66 mg per kg weekly, so about 16.5 mg for a 25 kg child, against roughly 0.2 to 0.3 mg per kg per week for daily GH. You are injecting far more mass to achieve a comparable effect. That mass has a practical consequence that shows up in the trial data: injection-site pain, erythema and pruritus were more frequent with somatrogon than with daily somatropin, and the larger weekly injection volume is the recognised explanation. Downstream, receptor pharmacology is conventional - dimer realignment, JAK2, STAT5b, hepatic IGF-1. Deal's phase 3 trial demonstrated non-inferior annual height velocity against daily somatropin, which is the endpoint that matters in children.

What usually goes wrong

The milligram numbers frighten people, and they should be explained rather than compared to somatropin. 16.5 mg a week for a 25 kg child looks enormous next to a daily GH dose measured in fractions of a milligram, but CTP adds mass without adding potency - it is not a bigger dose of GH, it is a bigger molecule. The genuine practical downside is the injection: more volume, more frequent site pain, erythema and pruritus than daily somatropin, and in a child that matters for adherence. Site rotation and cold-injection technique help. Anti-drug antibodies are common in the trials and did not affect efficacy or safety, so a positive antibody result should not by itself trigger a change. The class warnings apply: intracranial hypertension, slipped capital femoral epiphysis presenting as new hip or knee pain, and unmasked adrenal insufficiency.

Titration ladder

  1. —Paediatric, label dose — 0.66 mg per kg body weight once weekly, same day each week, any time of day, rotating sites. For a 25 kg child that is 16.5 mg weekly. There is no titration ladder - the dose is weight-based and recalculated as the child grows.

Bloodwork worth running

MarkerWhenWhy it matters
Growth velocity and height standard deviation scorePer paediatric endocrine protocol; the phase 3 trial assessed height velocity at 12 months.The primary efficacy measure in the only approved indication. Somatrogon is dosed by weight rather than titrated against IGF-1, so growth is the endpoint that actually drives decisions.Act if: Inadequate velocity prompts an adherence check and a weight recalculation before anything else.
IGF-1 standard deviation scoreAt a consistent point in the weekly cycle, periodically.Used as a safety check for over-replacement rather than as the titration target, which is a genuine difference from somapacitan and lonapegsomatropin.Act if: Persistently high IGF-1 SDS prompts a dose review even though the dose is weight-based.
Fasting glucose and HbA1cBaseline and periodically.GH class effect.Act if: A rise into the prediabetic range warrants review.
Free T4, TSH and adrenal statusBaseline and periodically.GH unmasks central hypothyroidism and compensated adrenal insufficiency, both common in the hypopituitary paediatric population.Act if: Address before escalating anything.
Anti-drug antibodiesOnly on unexplained loss of response.Common in the trials without demonstrable loss of efficacy or safety impact, which is worth knowing so that a positive result is not over-interpreted.Act if: No action for antibodies alone; investigate if growth velocity falls.

Pharmacokinetics

Crosses blood-brain barrier
no
Metabolism
Proteolytic catabolism of the fusion protein. The CTP domains are not enzymatically cleaved off to release free GH - somatrogon acts as the intact fusion protein, which is why its per-molecule receptor potency is reduced.
Elimination
Not characterised in the sources resolved here. Reduced renal filtration is the mechanistic basis of the extended half-life.

Receptor targets

  • Growth hormone receptor (GHR) — Reduced intrinsic potency per molecule relative to unmodified somatropin, because of the steric bulk of the CTP domains - compensated by dosing much higher milligram amounts

    Conventional receptor dimer realignment, JAK2 transphosphorylation, STAT5b signalling, hepatic IGF-1 transcription.

  • Renal glomerular filtration (evaded, not targeted) — Not applicable

    Increased hydrodynamic radius and negative charge from three O-glycosylated CTP domains slow filtration, which is the entire basis of the weekly dosing interval.

  • Hepatic IGF-1 production — Not applicable

    IGF-1 elevation across the weekly interval, used to check for over- or under-replacement rather than as the primary titration target.

Trials

  • Deal et al., efficacy and safety of weekly somatrogon versus daily somatropin in children with growth hormone deficiency - a phase 3 study 3 · 52 weeks · 2022

    Annual height velocity at 12 months. Weekly somatrogon was non-inferior to daily somatropin. Injection-site reactions were more frequent with somatrogon. This is the trial behind the approvals in the EU, Japan, Canada and the US.

  • Stawerska et al., three-year extension of the phase 3 somatrogon trial in children with growth hormone deficiency 3 extension · 156 weeks · 2026

    Three years of safety and efficacy follow-up in children continuing weekly somatrogon.

What to expect, and when

IGF-1 rises within the first week of dosing. Growth velocity is the endpoint and it is assessed at 12 months in the registration trial, with extension data now out to three years. There is no meaningful subjective onset in the way there is with adult GH use - this is a paediatric growth therapy and the timescale is measured in centimetres per year.

Stacking and comparisons

Nothing to stack. Somatrogon is GH delivered weekly and replaces daily somatropin rather than adding to it. Secretagogues are pointless alongside it. The interactions are the standard GH set: glucocorticoid dose adjustment may be needed in either direction, oral oestrogen blunts the IGF-1 response, and insulin requirements may rise.

Against lonapegsomatropin: lonapegsomatropin releases unmodified somatropin, so there is no question about tissue distribution or reduced receptor potency; somatrogon is a permanently modified fusion protein with reduced per-molecule potency and larger injection volumes. On the endpoint that matters, both showed non-inferiority to daily GH. Against somapacitan: somapacitan has both adult and paediatric indications, somatrogon is paediatric-only in most jurisdictions, and somapacitan's albumin binding is reversible rather than a permanent structural addition. Against daily somatropin: non-inferior height velocity with one injection a week instead of seven, at more injection-site discomfort and higher cost. The CTP platform's real distinction is that it is a naturally evolved half-life extension mechanism rather than a synthetic one, which is elegant but has not translated into a demonstrated clinical advantage over the alternatives.

Rough cost

$2500–$6000/month. Prescription biologic pricing, weight-dependent in children and running into the thousands of dollars a month. Access is through insurance and specialty pharmacy. There is no grey market for this product. Figures are approximate.

Genuinely uncertain

  • The Ngenla label was not retrieved in this session, so no pharmacokinetic figures - half-life, tmax, volume of distribution, clearance, steady state - are asserted here. The Core record's 'roughly a day and a half' half-life is not verified.
  • No molecular weight is given because the fusion protein's mass depends on glycosylation and was not resolved.
  • The exact CTP construct - one N-terminal and two C-terminal copies - is consistently reported in secondary sources but was not confirmed against a primary structural reference, so the sequence entry is unverified.
  • The reduced per-molecule receptor potency is the standard explanation for the large milligram dose and is mechanistically sound, but no quantitative potency comparison was resolved.
  • There is no adult indication in most jurisdictions and no adult efficacy data resolved here.
  • Long-term consequences of chronic exposure to a CTP fusion protein from childhood are not established beyond the three-year extension.

Papers